Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2007

View Archived Issues

Modest weight loss seen with pharmacotherapy for obesity/overweight

Gabapentin shows potential for treatment and prevention of high-altitude headache

Brivaracetam well tolerated and safe in patients with partial-onset seizures

Carisbamate reduces frequency of partial-onset seizures

MediGene and Celltrion sign agreement for anti-L1 monoclonal antibody for cancer

Inspire initiates phase III clinical trial of epinastine nasal spray for seasonal allergic rhinitis

Mitsubishi Tanabe reports first half ended September 30, 2007

Plethora reports positive preliminary results from phase II study of PSD-503

Nymox reports positive results from clinical study of NX-1207

Eurand completes gastrointestinal bioavailability study of Zentase for chronic pancreatitis

Valeant initiates phase IIa trial of retigabine for postherpetic neuralgia

LifeCycle initiates phase I clinical trial of sirolimus for organ rejection after transplantation

Regeneron and sanofi-aventis enter collaboration for fully human therapeutic antibodies

AnGes signs licensing agreement with Meyer for NF-kappaB decoy in the U.S. and Europe

Roche accepts FDA recommendation to add stronger warning label to Tamiflu

Celsion reports positive results from animal and stability studies of liposomal docetaxel

ChemGenex receives shareholder approval to demerge Verva

Cosmo reports positive results from phase II trial of Rifamycin SV MMX for diarrhea

Recent Novartis and Almirall patents impart novel therapeutic agents for respiratory disorders

New analgesic agents described in recent patent literature

FDA advisory panel recommends approval of Promus/Xience V

FDA issues approvable letter in response to Mylan's NDA for nebivolol for hypertension

FDA approves Alcon's Triesence for use in eye surgery

Chugai and Roche submit MAA to EMEA for Actemra for severe rheumatoid arthritis

FDA approves Eli Lilly's Cymbalta for major depressive disorder